Trials / Completed

CompletedNCT00316784

IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA

A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 704 (planned)

Sponsor: IDEA AG · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

The study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety. The study is designed with three dose levels and one placebo control.

Conditions

Osteoarthritis; Knee

Interventions

Type	Name	Description
DRUG	IDEA-033 (and rescue medication)

Timeline

Start date: 2005-07-01
Completion: 2006-05-01
First posted: 2006-04-21
Last updated: 2009-03-20

Source: ClinicalTrials.gov record NCT00316784. Inclusion in this directory is not an endorsement.